Rifaximin in non‐alcoholic steatohepatitis: An open‐label pilot study

Rifaximin in non‐alcoholic steatohepatitis: An open‐label pilot study

Aim Gut microbial dysbiosis is implicated in the pathogenesis of non‐alcoholic steatohepatitis (NASH). We investigated downstream effects of gut microbiota modulation on markers of hepatic inflammation, steatosis, and hepatic and peripheral insulin sensitivity in patients with NASH using rifaximin t...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology research Vol. 48; no. 1; pp. 69 - 77
Main Authors: Cobbold, Jeremy F.L., Atkinson, Stephen, Marchesi, Julian R., Smith, Ann, Wai, Sann N., Stove, Julie, Shojaee‐Moradie, Fariba, Jackson, Nicola, Umpleby, A. Margot, Fitzpatrick, Julie, Thomas, E. Louise, Bell, Jimmy D., Holmes, Elaine, Taylor‐Robinson, Simon D., Goldin, Robert D., Yee, Michael S., Anstee, Quentin M., Thursz, Mark R.
Format: Journal Article
Language:English
Published: Netherlands Wiley Subscription Services, Inc 01-01-2018
Subjects:
Alanine
Alanine transaminase
antibiotic
Biopsy
Diabetes
Diabetes mellitus
Dysbacteriosis
Fatty liver
Fecal microflora
hippurate
Homeostasis
Insulin
Insulin resistance
Intestinal microflora
Microbiota
NAFLD
non‐alcoholic steatohepatitis
Steatosis
antibiotic
microbiota
NAFLD
hippurate
insulin resistance
non-alcoholic steatohepatitis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim Gut microbial dysbiosis is implicated in the pathogenesis of non‐alcoholic steatohepatitis (NASH). We investigated downstream effects of gut microbiota modulation on markers of hepatic inflammation, steatosis, and hepatic and peripheral insulin sensitivity in patients with NASH using rifaximin therapy. Methods Patients with biopsy‐proven NASH and elevated aminotransferase values were included in this open‐label pilot study, all receiving 6 weeks rifaximin 400 mg twice daily, followed by a 6‐week observation period. The primary endpoint was change in alanine aminotransferase (ALT) after 6 weeks of rifaximin. Secondary endpoints were change in hepatic lipid content and insulin sensitivity measured with a hyperinsulinemic–euglycemic clamp. Results Fifteen patients (13 men and 2 women) with a median (range) age of 46 (32–63) years were included. Seven had diabetes on oral hypoglycemic medications and 8 had no diabetes. After 6 weeks of therapy, no differences were seen in ALT (55 [33–191] vs. 63 [41–218] IU/L, P = 0.41), peripheral glucose uptake (28.9 [19.4–48.3] to 25.5 [17.7–47.9] μmol/kg/min, P = 0.30), hepatic insulin sensitivity (35.2 [15.3–51.7]% vs. 30.0 [10.8–50.5]%, P = 0.47), or hepatic lipid content (21.6 [2.2–46.2]% vs. 24.8 [1.7–59.3]%, P = 0.59) before and after rifaximin treatment. After 12 weeks from baseline, serum ALT increased to 83 (30–217) IU/L, P = 0.02. There was a significant increase in the homeostasis model assessment–estimated insulin resistance index (P = 0.05). The urinary metabolic profile indicated a significant reduction in urinary hippurate with treatment, which reverted to baseline after cessation of rifaximin, although there was no consistent difference in relative abundance of fecal microbiota with treatment. Conclusion These data do not indicate a beneficial effect of rifaximin in patients with NASH.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1386-6346
1872-034X
DOI:10.1111/hepr.12904